Voyager Therapeutics (VYGR) Stock Forecast, Price Target & Predictions
VYGR Stock Forecast
Voyager Therapeutics stock forecast is as follows: an average price target of $14.50 (represents a 81.25% upside from VYGR’s last price of $8.00) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VYGR Price Target
The average price target for Voyager Therapeutics (VYGR) is $14.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $8.00. This represents a potential 81.25% upside from VYGR's last price of $8.00.
VYGR Analyst Ratings
According to 2 Wall Street analysts, Voyager Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VYGR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Voyager Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 25, 2024 | Jack Allen | Robert W. Baird | $18.00 | $6.04 | 198.01% | 125.00% |
| May 14, 2024 | Laura Chico | Wedbush | $8.00 | $8.48 | -5.66% | - |
| Jan 02, 2024 | Jim Birchenough | Wells Fargo | $14.00 | $9.00 | 55.56% | 75.00% |
| May 10, 2023 | Joon Lee | Truist Financial | $18.00 | $9.88 | 82.19% | 125.00% |
The latest Voyager Therapeutics stock forecast, released on Sep 25, 2024 by Jack Allen from Robert W. Baird, set a price target of $18.00, which represents a 198.01% increase from the stock price at the time of the forecast ($6.04), and a 125.00% increase from VYGR last price ($8.00).
Voyager Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $18.00 | $18.00 | $13.33 |
| Last Closing Price | $8.00 | $8.00 | $8.00 |
| Upside/Downside | 125.00% | 125.00% | 66.63% |
In the current month, the average price target of Voyager Therapeutics stock is $18.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 125.00% increase as opposed to Voyager Therapeutics's last price of $8.00. This month's average price target is down 0.00% compared to last quarter, and up 35.03% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | Wedbush | Buy | Buy | Hold |
| Jul 31, 2024 | Wedbush | Buy | Buy | Hold |
| May 14, 2024 | Wedbush | Neutral | Neutral | Hold |
| May 10, 2023 | UBS | - | Buy | Initialise |
Voyager Therapeutics's last stock rating was published by Wedbush on Oct 16, 2024. The company gave VYGR a "Buy" rating, the same as its previous rate.
Voyager Therapeutics Financial Forecast
Voyager Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.85M | $150.48M | $-41.09M | $41.09M | $712.00K | $658.00K | $28.07M | $1.48M | $1.36M | $6.50M | $6.54M | $117.84M | $28.68M | $18.07M | $32.67M | $20.43M |
| Avg Forecast | $50.42M | $47.80M | $45.32M | $42.97M | $9.29M | $21.62M | $21.12M | $9.29M | $11.29M | $11.70M | $9.51M | $9.48M | $20.63M | $2.91M | $1.60M | $8.37M | $3.73M | $9.42M | $7.03M | $12.71M | $4.30M | $2.14M | $4.18M | $7.55M | $16.59M | $15.05M | $16.52M | $13.55M | $9.93M | $6.88M |
| High Forecast | $50.42M | $47.80M | $45.32M | $42.97M | $9.29M | $21.62M | $21.12M | $9.29M | $11.29M | $19.44M | $9.51M | $9.48M | $23.05M | $2.91M | $1.60M | $8.37M | $3.73M | $9.42M | $7.03M | $12.71M | $4.30M | $2.14M | $4.18M | $7.55M | $16.59M | $15.05M | $16.52M | $13.55M | $9.93M | $6.88M |
| Low Forecast | $50.42M | $47.80M | $45.32M | $42.97M | $9.29M | $21.62M | $21.12M | $9.29M | $11.29M | $3.04M | $9.51M | $9.48M | $19.22M | $2.91M | $1.60M | $8.37M | $3.73M | $9.42M | $7.03M | $12.71M | $4.30M | $2.14M | $4.18M | $7.55M | $16.59M | $15.05M | $16.52M | $13.55M | $9.93M | $6.88M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.03% | 17.99% | -11.01% | 4.36% | 0.10% | 0.05% | 6.53% | 0.69% | 0.33% | 0.86% | 0.39% | 7.83% | 1.74% | 1.33% | 3.29% | 2.97% |
Voyager Therapeutics's average Quarter revenue forecast for Sep 23 based on 4 analysts is $2.91M, with a low forecast of $2.91M, and a high forecast of $2.91M. VYGR's average Quarter revenue forecast represents a -40.09% decrease compared to the company's last Quarter revenue of $4.85M (Jun 23).
Voyager Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.43M | $122.88M | $-24.56M | $15.78M | $-18.16M | $-18.54M | $7.19M | $-23.91M | $-28.93M | $-20.38M | $-14.94M | $86.67M | $-7.75M | $-23.42M | $-11.82M | $-14.29M |
| Avg Forecast | $-18.22M | $-17.27M | $-16.38M | $-15.53M | $-3.36M | $-7.81M | $-7.63M | $-3.36M | $-4.08M | $-4.23M | $-3.44M | $4.46M | $-7.46M | $-1.05M | $-578.83K | $4.77M | $-1.35M | $-3.40M | $-2.54M | $5.10M | $-1.55M | $-774.39K | $-1.51M | $-22.84M | $-5.99M | $-5.44M | $-5.97M | $-27.28M | $-3.59M | $-2.48M |
| High Forecast | $-18.22M | $-17.27M | $-16.38M | $-15.53M | $-3.36M | $-7.81M | $-7.63M | $-3.36M | $-4.08M | $-1.10M | $-3.44M | $5.35M | $-6.94M | $-1.05M | $-578.83K | $5.72M | $-1.35M | $-3.40M | $-2.54M | $6.12M | $-1.55M | $-774.39K | $-1.51M | $-18.28M | $-5.99M | $-5.44M | $-5.97M | $-21.82M | $-3.59M | $-2.48M |
| Low Forecast | $-18.22M | $-17.27M | $-16.38M | $-15.53M | $-3.36M | $-7.81M | $-7.63M | $-3.36M | $-4.08M | $-7.03M | $-3.44M | $3.57M | $-8.33M | $-1.05M | $-578.83K | $3.81M | $-1.35M | $-3.40M | $-2.54M | $4.08M | $-1.55M | $-774.39K | $-1.51M | $-27.41M | $-5.99M | $-5.44M | $-5.97M | $-32.73M | $-3.59M | $-2.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.93% | 25.77% | 18.21% | -4.64% | 7.15% | -3.64% | -4.63% | 30.88% | 19.18% | 0.89% | 2.49% | -15.93% | 1.30% | 0.86% | 3.29% | 5.75% |
4 analysts predict VYGR's average Quarter EBITDA for Jun 23 to be $-578.83K, with a high of $-578.83K and a low of $-578.83K. This is -100.47% lower than Voyager Therapeutics's previous annual EBITDA (Mar 23) of $122.88M.
Voyager Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-22.21M | $124.04M | $-23.63M | $17.62M | $-18.87M | $-21.29M | $5.71M | $-25.14M | $-30.12M | $-21.65M | $-15.93M | $85.61M | $-8.68M | $-24.26M | $-12.57M | $-15.01M |
| Avg Forecast | $-34.96M | $-34.97M | $-33.02M | $-33.03M | $-33.69M | $-25.84M | $-26.72M | $-32.61M | $-27.14M | $-25.70M | $-23.62M | $-33.55M | $-16.68M | $-33.54M | $-32.83M | $-35.88M | $-31.50M | $-18.31M | $-27.54M | $-38.37M | $-36.01M | $-43.15M | $-42.02M | $-24.27M | $-32.32M | $-10.87M | $-41.35M | $-28.26M | $-41.80M | $-41.94M |
| High Forecast | $-34.96M | $-34.97M | $-33.02M | $-33.03M | $-33.69M | $-25.84M | $-26.72M | $-32.61M | $-27.14M | $-15.32M | $-23.62M | $-26.84M | $-14.42M | $-33.54M | $-32.83M | $-28.70M | $-31.50M | $-18.31M | $-27.54M | $-30.70M | $-36.01M | $-43.15M | $-42.02M | $-19.42M | $-32.32M | $-10.87M | $-41.35M | $-22.60M | $-41.80M | $-41.94M |
| Low Forecast | $-34.96M | $-34.97M | $-33.02M | $-33.03M | $-33.69M | $-25.84M | $-26.72M | $-32.61M | $-27.14M | $-32.13M | $-23.62M | $-40.26M | $-17.53M | $-33.54M | $-32.83M | $-43.06M | $-31.50M | $-18.31M | $-27.54M | $-46.05M | $-36.01M | $-43.15M | $-42.02M | $-29.13M | $-32.32M | $-10.87M | $-41.35M | $-33.91M | $-41.80M | $-41.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.68% | -3.46% | 0.75% | -0.96% | 0.69% | 0.55% | -0.16% | 0.58% | 0.72% | 0.89% | 0.49% | -7.88% | 0.21% | 0.86% | 0.30% | 0.36% |
Voyager Therapeutics's average Quarter net income forecast for Jun 23 is $-32.83M, with a range of $-32.83M to $-32.83M. VYGR's average Quarter net income forecast represents a -126.47% decrease compared to the company's last Quarter net income of $124.04M (Mar 23).
Voyager Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.29M | $9.03M | $8.46M | $7.31M | $7.55M | $7.66M | $8.35M | $8.71M | $10.44M | $9.74M | $8.27M | $8.28M | $8.24M | $10.21M | $9.89M | $8.46M |
| Avg Forecast | $24.69M | $23.41M | $22.19M | $21.04M | $4.55M | $10.59M | $10.34M | $4.55M | $5.53M | $5.73M | $4.66M | $4.64M | $10.10M | $1.42M | $784.40K | $4.10M | $1.83M | $4.61M | $3.44M | $6.23M | $2.10M | $1.05M | $2.04M | $3.70M | $8.12M | $7.37M | $8.09M | $11.89M | $4.86M | $3.37M |
| High Forecast | $24.69M | $23.41M | $22.19M | $21.04M | $4.55M | $10.59M | $10.34M | $4.55M | $5.53M | $9.52M | $4.66M | $4.64M | $11.29M | $1.42M | $784.40K | $4.10M | $1.83M | $4.61M | $3.44M | $6.23M | $2.10M | $1.05M | $2.04M | $3.70M | $8.12M | $7.37M | $8.09M | $14.26M | $4.86M | $3.37M |
| Low Forecast | $24.69M | $23.41M | $22.19M | $21.04M | $4.55M | $10.59M | $10.34M | $4.55M | $5.53M | $1.49M | $4.66M | $4.64M | $9.41M | $1.42M | $784.40K | $4.10M | $1.83M | $4.61M | $3.44M | $6.23M | $2.10M | $1.05M | $2.04M | $3.70M | $8.12M | $7.37M | $8.09M | $9.51M | $4.86M | $3.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.57% | 2.20% | 4.63% | 1.58% | 2.19% | 1.23% | 3.97% | 8.30% | 5.10% | 2.64% | 1.02% | 1.12% | 1.02% | 0.86% | 2.03% | 2.51% |
Voyager Therapeutics's average Quarter SG&A projection for Sep 23 is $1.42M, based on 4 Wall Street analysts, with a range of $1.42M to $1.42M. The forecast indicates a -82.83% fall compared to VYGR last annual SG&A of $8.29M (Jun 23).
Voyager Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.51 | $3.05 | $-0.61 | $0.46 | $-0.49 | $-0.56 | $0.15 | $-0.67 | $-0.80 | $-0.58 | $-0.43 | $2.30 | $-0.23 | $-0.66 | $-0.35 | $-0.41 |
| Avg Forecast | $-0.61 | $-0.61 | $-0.57 | $-0.57 | $-0.58 | $-0.45 | $-0.46 | $-0.56 | $-0.47 | $-0.45 | $-0.41 | $-0.44 | $-0.29 | $-0.58 | $-0.57 | $-0.37 | $-0.55 | $-0.32 | $-0.48 | $-0.37 | $-0.62 | $-0.75 | $-0.73 | $-0.64 | $-0.56 | $-0.19 | $-0.72 | $-0.79 | $-0.72 | $-0.73 |
| High Forecast | $-0.61 | $-0.61 | $-0.57 | $-0.57 | $-0.58 | $-0.45 | $-0.46 | $-0.56 | $-0.47 | $-0.27 | $-0.41 | $-0.44 | $-0.25 | $-0.58 | $-0.57 | $-0.37 | $-0.55 | $-0.32 | $-0.48 | $-0.37 | $-0.62 | $-0.75 | $-0.73 | $-0.64 | $-0.56 | $-0.19 | $-0.72 | $-0.79 | $-0.72 | $-0.73 |
| Low Forecast | $-0.61 | $-0.61 | $-0.57 | $-0.57 | $-0.58 | $-0.45 | $-0.46 | $-0.56 | $-0.47 | $-0.56 | $-0.41 | $-0.44 | $-0.30 | $-0.58 | $-0.57 | $-0.37 | $-0.55 | $-0.32 | $-0.48 | $-0.37 | $-0.62 | $-0.75 | $-0.73 | $-0.64 | $-0.56 | $-0.19 | $-0.72 | $-0.79 | $-0.72 | $-0.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | -8.22% | 1.12% | -1.45% | 1.03% | 1.51% | -0.24% | 0.90% | 1.10% | 0.90% | 0.77% | -12.21% | 0.32% | 0.84% | 0.48% | 0.56% |
According to 4 Wall Street analysts, Voyager Therapeutics's projected average Quarter EPS for Jun 23 is $-0.57, with a low estimate of $-0.57 and a high estimate of $-0.57. This represents a -118.65% decrease compared to VYGR previous annual EPS of $3.05 (Mar 23).
Voyager Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.50 | $3.67 | 634.00% | Buy |
| PDSB | PDS Bio | $3.10 | $9.00 | 190.32% | Buy |
| INZY | Inozyme Pharma | $5.15 | $14.67 | 184.85% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.66 | $7.00 | 163.16% | Buy |
| DAWN | Day One Biopharmaceuticals | $15.08 | $38.80 | 157.29% | Buy |
| LPTX | Leap Therapeutics | $2.33 | $5.50 | 136.05% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $20.84 | $45.38 | 117.75% | Buy |
| TERN | Terns Pharmaceuticals | $7.50 | $14.25 | 90.00% | Buy |
| ANNX | Annexon | $7.63 | $14.00 | 83.49% | Buy |
| VYGR | Voyager Therapeutics | $8.01 | $14.50 | 81.02% | Buy |
| MREO | Mereo BioPharma Group | $4.56 | $6.75 | 48.03% | Buy |
| PRQR | ProQR Therapeutics | $4.49 | $3.63 | -19.15% | Buy |
| HOOK | HOOKIPA Pharma | $4.17 | $3.00 | -28.06% | Buy |
VYGR Forecast FAQ
Is Voyager Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Voyager Therapeutics (VYGR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VYGR's total ratings.
What is VYGR's price target?
Voyager Therapeutics (VYGR) average price target is $14.5 with a range of $8 to $18, implying a 81.25% from its last price of $8. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Voyager Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VYGR stock, the company can go up by 81.25% (from the last price of $8 to the average price target of $14.5), up by 125.00% based on the highest stock price target, and down by 0% based on the lowest stock price target.
Can Voyager Therapeutics stock reach $12?
VYGR's average twelve months analyst stock price target of $14.5 supports the claim that Voyager Therapeutics can reach $12 in the near future.
What is Voyager Therapeutics's current price target trend?
1 Wall Street analyst forecast a $18 price target for Voyager Therapeutics (VYGR) this month, up 125.00% from its last price of $8. Compared to the last 3 and 12 months, the average price target increased by 125.00% and increased by 66.62%, respectively.
What are Voyager Therapeutics's analysts' financial forecasts?
Voyager Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $61.33M (high $61.33M, low $61.33M), average EBITDA is $-22.163M (high $-22.163M, low $-22.163M), average net income is $-119M (high $-119M, low $-119M), average SG&A $30.03M (high $30.03M, low $30.03M), and average EPS is $-2.059 (high $-2.059, low $-2.059). VYGR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $186.51M (high $186.51M, low $186.51M), average EBITDA is $-67.401M (high $-67.401M, low $-67.401M), average net income is $-136M (high $-136M, low $-136M), average SG&A $91.34M (high $91.34M, low $91.34M), and average EPS is $-2.356 (high $-2.356, low $-2.356).
Did the VYGR's actual financial results beat the analysts' financial forecasts?
Based on Voyager Therapeutics's last annual report (Dec 2022), the company's revenue was $40.91M, beating the average analysts forecast of $32.89M by 24.36%. Apple's EBITDA was $-50.837M, beating the average prediction of $-2.193M by 2218.05%. The company's net income was $-46.408M, missing the average estimation of $-116M by -59.90%. Apple's SG&A was $30.98M, beating the average forecast of $16.11M by 92.32%. Lastly, the company's EPS was $-1.21, missing the average prediction of $-1.711 by -29.28%. In terms of the last quarterly report (Jun 2023), Voyager Therapeutics's revenue was $4.85M, beating the average analysts' forecast of $1.6M by 202.99%. The company's EBITDA was $-25.426M, beating the average prediction of $-579K by 4292.62%. Voyager Therapeutics's net income was $-22.208M, missing the average estimation of $-32.831M by -32.36%. The company's SG&A was $8.29M, beating the average forecast of $784.4K by 957.37%. Lastly, the company's EPS was $-0.51, missing the average prediction of $-0.569 by -10.33%